The Food and Drug Administration (FDA) has approved a new nonhormonal menopause medication to treat hot flashes.
Elinzanetant, which was given the green light Friday under the brand name Lynkuet, belongs to a new class of drugs designed to target what is believed to be a key mechanism responsible for menopause-related hot flashes and night sweats. Lynkuet, a once-daily pill, is expected to be available in the United States starting in November, Bayer said.
A similar drug, Veozah (fezolinetant), was approved in 2023.
Please select this link to read the complete article from The Washington Post.